Current Problems in Cardiology
Volume 34, Issue 8 , Pages 330-349 , August 2009

Management of Cardiogenic Shock: Focus on Tissue Perfusion

References 

  1. Wu AH, Parsons L, Every NR, et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002;40:1389–1394
  2. Topalian S, Ginsberg F, Parrillo JE. Cardiogenic shock. Crit Care Med. 2008;36:S66–S74
  3. Dickstein K, Cohen-Solal A, Filippatos GS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388–2442
  4. Singh M, White J, Hasdai D, et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: Insights from the GUSTO-I trial. J Am Coll Cardiol. 2007;50:1752–1758
  5. Valk SDA, Lagrand WK, van de Sande AJM, et al. Good survival rates in patients with acute myocardial infarction treated with an intra-aortic balloon pump. Eur Heart J. 2006;27:908
  6. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341:625–634
  7. Wong SC, Sanborn T, Sleeper LA, et al. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?. J Am Coll Cardiol. 2000;36:1077–1083
  8. Ammann P, Straumann E, Naegeli B, et al. Long-term results after acute percutaneous transluminal coronary angioplasty in acute myocardial infarction and cardiogenic shock. Int J Cardiol. 2002;82:127–131
  9. Alpert JS, Becker RC. Cardiogenic shock: Elements of etiology, diagnosis, and therapy. Clin Cardiol. 1993;16:182–190
  10. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977;39:137–145
  11. HFSA. Comprehensive heart failure practice guideline. J Cardiovasc Fail. 2006;12:e1–e2
  12. Elkayam U, Janmohamed M, Habib M, et al. Vasodilators in the management of acute heart failure. Crit Care Med. 2008;36:S95–S105
  13. Hollenberg SM. Vasodilators in acute heart failure. Heart Fail Rev. 2007;12:143–147
  14. Elkayam U, Roth A, Kumar A, et al. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. Am J Cardiol. 1987;60:1106–1111
  15. Elkayam U, Bitar F, Akhter MW, et al. Intravenous nitroglycerin in the treatment of decompensated heart failure: Potential benefits and limitations. J Cardiovasc Pharmacol Ther. 2004;9:227–241
  16. Spronk PE, Ince C, Gardien MJ, et al. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet. 2002;360:1395–1396
  17. den Uil CA, Lagrand WK, Spronk PE, et al. Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure. Eur J Heart Fail. 2009;11(4):386–390
  18. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. J Am Med Assoc. 2002;287:628–640
  19. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19:918–925
  20. Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation. 1987;76:577–584
  21. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990;16:923–931
  22. Tsai SC, Adamik R, Manganiello VC, et al. Effects of nitroprusside and nitroglycerin on cGMP content and PGI2 formation in aorta and vena cava. Biochem Pharmacol. 1989;38:61–65
  23. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52:200–207
  24. Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med. 2008;36:S106–S111
  25. Endoh M, Yanagisawa T, Taira N, et al. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation. 1986;73:117–133
  26. Benotti JR, Grossman W, Braunwald E, et al. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation. 1980;62:28–34
  27. Naccarelli GV, Gray EL, Dougherty AH, et al. Amrinone: Acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am J Cardiol. 1984;54:600–604
  28. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet. 2002;360:196–202
  29. Nanas JN, Papazoglou PP, Terrovitis JV, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol. 2004;94:1329–1332
  30. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431–435
  31. Russ MA, Prondzinsky R, Christoph A, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med. 2007;35:2732–2739
  32. Delle Karth G, Buberl A, Geppert A, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anæsthesiol Scand. 2003;47:1251–1256
  33. García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, et al. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8:723–728
  34. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. J Am Med Assoc. 2007;297:1883–1891
  35. Fuhrmann JT, Schmeisser A, Schulze MR, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36:2257–2266
  36. Anderson RD, Ohman EM, Holmes DRJ, et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the GUSTO-I study (Global utilization of streptokinase and TPA for occluded coronary arteries). J Am Coll Cardiol. 1997;30:708–715
  37. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?. J Am Coll Cardiol. 2000;36:1123–1129
  38. Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2. Am Heart J. 2001;141:933–939
  39. Tsai FC, Marelli D, Laks H, et al. Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. Am J Transplant. 2002;2:646–651
  40. Idelchik GM, Simpson L, Civitello AB, et al. Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device implantation. J Heart Lung Transplant. 2008;27:106–111
  41. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152(469):e1–e8
  42. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26:1276–1283
  43. Vecchio S, Chechi T, Giuliani G, et al. Use of Impella recover 2.5 left ventricular assist device in patients with cardiogenic shock or undergoing high-risk percutaneous coronary intervention procedures: Experience of a high-volume center. Minerva Cardioangiol. 2008;56:391–399
  44. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. J Am Med Assoc. 2006;295:2511–2515
  45. Jeger RV, Tseng CH, Hochman JS, et al. Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—A report from the Should we revascularize occluded coronaries for cardiogenic shock? ((shock) trial registry). Am Heart J. 2006;152:686–692
  46. Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. J Am Med Assoc. 2005;294:448–454
  47. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:E1–E211
  48. White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: Results from the should we emergently revascularize occluded coronaries for cardiogenic shock (shock) trial. Circulation. 2005;112:1992–2001
  49. Jeger RV, Radovanovic D, Hunziker PR, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008;149:618–626
  50. Mann HJ, Nolan PE. Update on the management of cardiogenic shock. Curr Opin Crit Care. 2006;12:431–436
  51. Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340–348
  52. Lim N, Dubois MJ, De Backer D, et al. Do all nonsurvivors of cardiogenic shock die with a low cardiac index?. Chest. 2003;124:1885–1891
  53. Kohsaka S, Menon V, Lowe AM, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165:1643–1650
  54. Reynolds HR, Hochman JS. Cardiogenic shock, current concepts and improving outcomes. Circulation. 2008;117:686–697
  55. den Uil CA, Klijn E, Lagrand WK, et al. The microcirculation in health and critical disease. Prog Cardiovasc Dis. 2008;51:161–170
  56. Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J. 1998;19:761–765
  57. Reilly PM, Wilkins KB, Fuh KC, et al. The mesenteric hemodynamic response to circulatory shock: An overview. Shock. 2001;5:329–343
  58. De Backer D, Creteur J, Dubois MJ, et al. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am Heart J. 2004;147:91–99
  59. Hasdai D, Holmes DR, Califf RM, et al. Cardiogenic shock complicating acute myocardial infarction: Predictors of death. Am Heart J. 1999;138:21–31
  60. Smith I, Kumar P, Molloy S, et al. Base Excess and Lactate as prognostic indicators for patients admitted to intensive care. Intens Care Med. 2001;(27):74–83
  61. Geppert A, Dorninger A, Delle-Karth G, et al. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2006;34:2035–2042
  62. Nicholls SJ, Wang Z, Koeth R, et al. Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation. 2007;116:2315–2324
  63. Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol. 2008;127:228–232
  64. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation. 2003;107:2998–3002
  65. den Uil CA, Lagrand WK, Spronk PE, et al. Impaired sublingual microvascular perfusion during surgery with cardiopulmonary bypass: A pilot study. J Thorac Cardiovasc Surg. 2008;136:129–134
  66. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (Z nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000;101:1358–1361
  67. Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J. 2003;24:1287–1295
  68. Dzavík V, Cotter G, Reynolds HR, et al. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: A Phase II dose-ranging study. Eur Heart J. 2007;28:1109–1116
  69. Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: The TRIUMPH randomized controlled trial. J Am Med Assoc. 2007;297:1657–1666
  70. Kirschenbaum LA, Astiz ME, Rackow EC, et al. Microvascular response in patients with cardiogenic shock. Crit Care Med. 2000;28:1290–1294
  71. Struijker-Boudier HA, Rosei AE, Bruneval P, et al. Evaluation of the microcirculation in hypertension and cardiovascular disease. Eur Heart J. 2007;28:2834–2840
  72. Mueller HS, Evans R, Ayres SM. Effect of dopamine on hemodynamics and myocardial metabolism in shock following acute myocardial infarction in man. Circulation. 1978;57:361–365
  73. Keung EC, Siskind SJ, Sonneblick EH, et al. Dobutamine therapy in acute myocardial infarction. J Am Med Assoc. 1981;245:144–146
  74. Francis GS, Sharma B, Hodges M. Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J. 1982;103:995–1000
  75. Caldicott LD, Hawley K, Heppell R, et al. Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: A randomized double-blind trial. Eur Heart J. 1993;14:696–700
  76. Seino Y, Momomura S, Takano T, et al. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Crit Care Med. 1996;24:1490–1497
  77. Loh E, Elkayam U, Cody R, et al. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Cardiovasc Fail. 2001;7:114–121

 The authors have no conflict of interest to disclose.

PII: S0146-2806(09)00057-7

doi: 10.1016/j.cpcardiol.2009.04.002

Current Problems in Cardiology
Volume 34, Issue 8 , Pages 330-349 , August 2009

Article Tools

* Image Usage & Resolution